Overview

Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients

Status:
Withdrawn
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to obtain a pharmacokinetic profile (i.e. amount of drug in the blood over time) of Omecamtiv mecarbil in patients with stable heart failure.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Cytokinetics